Macrophage-Targeted Photodynamic Therapy

Photodynamic therapy (PDT) uses light activatable molecules that after illumination produce reactive oxygen species and unwanted tissue destruction. PDT has dual selectivity due to control of light delivery and to some extent selective photosensitizer (PS) accumulation in tumors or other diseased tissue, additional targeted selectivity of PS for disease is necessary. The delivery of drugs to selected lesions can be enhanced by the preparation of targeted macromolecular conjugates that employ cell type specific targeting by ligand-receptor recognition. Macrophages and monocytes express a scavenger-receptor that is a high-capacity route for delivering molecules into endocytic compartments in a cell-type specific manner. We have shown that by attaching PS to scavenger-receptor ligands it is possible to get three logs of selective cell killing in macrophages while leaving non-macrophage cells unharmed. The capability to selectively kill macrophages has applications in treating cancer and in the detection and therapy of vulnerable atherosclerotic plaque and possibly for autoimmune disease and some infections.

[1]  Michael R. Hamblin,et al.  Scavenger receptor-targeted photodynamic therapy of J774 tumors in mice: tumor response and concomitant immunity , 2002, SPIE BiOS.

[2]  J. Forrester.  Prevention of Plaque Rupture: A New Paradigm of Therapy , 2002, Annals of Internal Medicine.

[3]  V. Fuster,et al.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. , 1995, Circulation.

[4]  B. Říhová.  Targeting of drugs to cell surface receptors. , 1997, Critical reviews in biotechnology.

[5]  E. Falk.  Why do plaques rupture? , 1992, Circulation.

[6]  M. Krieger.  Molecular flypaper and atherosclerosis: structure of the macrophage scavenger receptor. , 1992, Trends in biochemical sciences.

[7]  Michael R Hamblin,et al.  On the mechanism of the tumour-localising effect in photodynamic therapy. , 1994, Journal of photochemistry and photobiology. B, Biology.

[8]  Y. Huang,et al.  Cytokine-induced macrophage differentiation: a tale of 2 genes. , 1999, Clinical and investigative medicine. Medecine clinique et experimentale.

[9]  M. Swanson,et al.  A phagosome of one's own: a microbial guide to life in the macrophage. , 2002, Current opinion in microbiology.

[10]  N. Neumann,et al.  Macrophage-Mediated Innate Host Defense Against Protozoan Parasites , 2002, Critical reviews in microbiology.

[11]  P CONSTANTINIDES,et al.  Rabbit arterial thrombosis production by systemic procedures. , 1961, Archives of pathology.

[12]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[13]  A. Harris,et al.  Secretion of epidermal growth factor by macrophages associated with breast carcinoma , 1993, The Lancet.

[14]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[15]  H. Kleinman,et al.  Tumor-associated macrophages as targets for cancer therapy. , 1998, Journal of the National Cancer Institute.

[16]  T. Kodama,et al.  Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system , 1998, Cellular and Molecular Life Sciences CMLS.

[17]  J. Plutzky,et al.  Atherosclerotic plaque rupture: emerging insights and opportunities. , 1999, The American journal of cardiology.

[18]  H. Nishino,et al.  PHOTOCYTOTOXICITY OF WATER‐SOLUBLE METALLOPORPHYRIN DERIVATIVES , 1993, Photochemistry and photobiology.

[19]  L. DiPietro,et al.  WOUND HEALING: THE ROLE OF THE MACROPHAGE AND OTHER IMMUNE CELLS , 1995, Shock.

[20]  P. Sansonetti,et al.  Host–pathogen interactions: the seduction of molecular cross talk , 2002, Gut.

[21]  Michael S Patterson,et al.  Direct Near-infrared Luminescence Detection of Singlet Oxygen Generated by Photodynamic Therapy in Cells In Vitro and Tissues In Vivo¶ , 2002, Photochemistry and photobiology.

[22]  M. Korbelik,et al.  Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. , 1997, British Journal of Cancer.

[23]  S. Basu,et al.  Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery , 1995, FEBS letters.

[24]  J L Witztum,et al.  The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. , 1992, Annual review of medicine.

[25]  J. Krosl,et al.  Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. , 1996, Cancer research.

[26]  H. Redmond,et al.  Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1 , 1998, Annals of Surgical Oncology.

[27]  Robert C. Bast,et al.  Tumor Necrosis Factor α as an Autocrine and Paracrine Growth Factor for Ovarian Cancer: Monokine Induction of Tumor Cell Proliferation and Tumor Necrosis Factor α Expression , 1993 .

[28]  T. Urano,et al.  Significance of Plasminogen Activators and Plasminogen Activator Inhibitors in Human Lung Cancer , 1992 .

[29]  Michael R Hamblin,et al.  Scavenger-Receptor Targeted Photodynamic Therapy¶ , 2000, Photochemistry and photobiology.

[30]  M. Korbelik,et al.  PHOTOFRIN ACCUMULATION IN MALIGNANT AND HOST CELL POPULATIONS OF A MURINE FIBROSARCOMA , 1995, Photochemistry and photobiology.

[31]  Hiroshi Maeda,et al.  Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.

[32]  M. Ochsner.  Photophysical and photobiological processes in the photodynamic therapy of tumours. , 1997, Journal of photochemistry and photobiology. B, Biology.

[33]  R. Bast,et al.  Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. , 1993, Cancer research.

[34]  Michael R. Hamblin,et al.  Macrophage-targeted photodynamic detection of vulnerable atherosclerotic plaque , 2003, SPIE BiOS.

[35]  A. Mantovani,et al.  Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[36]  N. Ismail,et al.  Current status of immune mechanisms of killing of intracellular microorganisms. , 2002, FEMS microbiology letters.

[37]  G. Bearman,et al.  Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis , 1996, The Lancet.

[38]  T. Dougherty.  An update on photodynamic therapy applications. , 2002, Journal of clinical laser medicine & surgery.

[39]  W. Cheong,et al.  Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy. , 2000, Circulation.

[40]  W. D. Fairlie,et al.  MIC‐1 is a novel TGF‐β superfamily cytokine associated with macrophage activation , 1999, Journal of leukocyte biology.

[41]  J. Muller,et al.  Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. , 1994, Journal of the American College of Cardiology.

[42]  M G Nichols,et al.  The Mechanism of Photofrin Photobleaching and Its Consequences for Photodynamic Dosimetry , 1997, Photochemistry and photobiology.

[43]  N. Van Rooijen.  The liposome-mediated macrophage 'suicide' technique. , 1989, Journal of immunological methods.

[44]  Y. Endo,et al.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. , 1998, British Journal of Cancer.

[45]  M. Korbelik,et al.  Photofrin accumulation in malignant and host cell populations of various tumours. , 1996, British Journal of Cancer.